DE19809785A1 - Radioimmunpharmakon zur Behandlung der HIV-1-Infektion - Google Patents
Radioimmunpharmakon zur Behandlung der HIV-1-InfektionInfo
- Publication number
- DE19809785A1 DE19809785A1 DE1998109785 DE19809785A DE19809785A1 DE 19809785 A1 DE19809785 A1 DE 19809785A1 DE 1998109785 DE1998109785 DE 1998109785 DE 19809785 A DE19809785 A DE 19809785A DE 19809785 A1 DE19809785 A1 DE 19809785A1
- Authority
- DE
- Germany
- Prior art keywords
- hiv
- radioimmunoconjugate
- monoclonal antibody
- epitope
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
- 1. Bergter W: Herstellung zehn monoklonaler Antikörper gegen das Affen-Immundefi zienzvirus SIVagmTYO-7 aus der Familie der Retroviren. Dissertation, Hannover 1990.
- 2. Blumenthal RD, Sharkey RM, Haywood L, et al.: Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131J-labeled monoclonal antibodies. Cancer Res 1992; 52: 6036-6044.
- 3. Blumenthal RD, Sharkey RM, Natale AM, et al.: Comparison of equitoxic radio immunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res 1994; 54: 142-151.
- 4. Eckert WA und Kartenberg J: Proteine: Standardmethoden der Molekular- und Zell biologie. Springer, Heidelberg 1996.
- 5. Fultz PN, Schwiebert RS, Su L, et al.: Effects of total lymphoid irradiation on SW- infected macaques. AIDS Res Hum Retroviruses 1995; 11(12): 1517-1527.
- 6. Kaminski MS, Zasadny KR, Francis IR, et al.: Radioimmunotherapy of B-cell lymphoma with [131J]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459-465.
- 7. Lidell E und Weeks I: Antikörper-Techniken. Spektrum Akademischer Verlag, Heidelberg 1996.
- 8. Moser E: Nuklearmedizin. In Kauffmann G, Moser E und Sauer R: Radiologie. Urban und Schwarzenberg, München 1996.
- 9. Muster T, Steindl F, Purtscher M, et al.: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67(11): 6642-6647.
- 10. Peters JH, Baumgarten H, Schulze M: Monoklonale Antikörper. Herstellung und Charakterisierung. Springer, Berlin 1996.
- 11. Press OW, Eary JF, Appelbaum FR, et al.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219-1224.
- 12. Press OW, Eary JF, Appelbaum FR, et al.: Phase H trial of 131J-B1(anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphoma. Lancet 1995; 346: 336-340.
- 13. Press OW, Eary JF, Appelbaum FR, et al.: Treatment of relapsed B-cell lymphomas with high dose radioimmunotherapy and bone marrow transplantation. In Goldenberg DM (ed.): Cancer Therapy with Radiolabeled Antibodies. Boca Raton, CRC Press 1995: pp 229-237.
- 14. Sauer R: Strahlenbiologie. In Kauffmann G, Moser E und Sauer R: Radiologie. Urban und Schwarzenberg, München 1996.
- 15. Sauer R: Strahlentherapie und Onkologie für MTA-R. Urban und Schwarzenberg, München 1998.
- 16. Xu Y, Conway B, Montaner JS, et al.: Effect of low-dose gamma radiation of HIV replication in human peripheral blood mononuclear cells. Photochem Photobiol 1996; 64(2): 238-241.
Claims (2)
daß es als immunologisch wirksame Komponente einen humanen oder murinen, gegebenenfalls humanisierten monoklonalen Antikörper gegen ein Epitop auf dem Oberflächenglykoprotein gp120 des HIV-1 zusammen mit pharmazeutischen Trägern und/oder Hilfsstoffen enthält,
oder daß es als immunologisch wirksame Komponente einen humanen oder murinen, gegebenenfalls humanisierten monoklonalen Antikörper gegen ein Epitop auf dem Transmembranglykoprotein gp41 des HIV-1 zusammen mit pharmazeutischen Trägern und/oder Hilfsstoffen enthält,
daß es als radioaktive Komponente 131J enthält,
oder daß es als radioaktive Komponente 32P enthält,
oder daß es als radioaktive Komponente 90Y enthält,
oder daß es als radioaktive Komponente 89Sr enthält.
daß das Radioimmunkonjugat intravenös unter ein- bis mehrtägiger stationärer Strah lenabschirmung mit einer Gesamtkörperdosis zwischen 50 bis 300 mCi einmalig oder in mehreren Zyklen appliziert wird,
daß das Radioimmunkonjugat nach Anspruch 1 unter dem Schutz einer antiretroviralen Standardtripeltherapie erfolgt,
und/oder daß das Radioimmunkonjugat nach Anspruch 1 unter dem Schutz einer Stammzelltransplantation erfolgt,
und/oder daß das Radioimmunkonjugat mit 131J als radioaktiver Komponente unter dem Schutz einer Schilddrüsenblockade nach bekanntem Muster erfolgt.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1998109785 DE19809785C2 (de) | 1998-03-08 | 1998-03-08 | Radioimmunpharmakon zur Behandlung der HIV-1-Infektion |
DE1998126307 DE19826307A1 (de) | 1998-03-08 | 1998-04-15 | CD4-Radioimmunpharmaka zur Behandlung der HIV-Infektion |
DE1998118843 DE19818843A1 (de) | 1998-03-08 | 1998-04-28 | Radioimmunpharmaka zur Therapie der Hepatitis C |
DE1998128732 DE19828732A1 (de) | 1998-03-08 | 1998-06-29 | Antivirale Radioimmunpharmaka auf der Basis von Alpha-Strahlern |
EP99919038A EP1061959A2 (de) | 1998-03-08 | 1999-03-05 | Radioimmunpharmakon zur behandlung der hiv-1-infektion |
AU36981/99A AU3698199A (en) | 1998-03-08 | 1999-03-05 | Radioimmuno-pharmacon for treating the hiv-1 infection |
PCT/DE1999/000598 WO1999045969A2 (de) | 1998-03-08 | 1999-03-05 | Radioimmunpharmakon zur behandlung der hiv-1-infektion |
JP2000535382A JP2002506051A (ja) | 1998-03-08 | 1999-03-05 | Hiv−1感染を治療するための放射免疫剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE1998109785 DE19809785C2 (de) | 1998-03-08 | 1998-03-08 | Radioimmunpharmakon zur Behandlung der HIV-1-Infektion |
Publications (2)
Publication Number | Publication Date |
---|---|
DE19809785A1 true DE19809785A1 (de) | 1999-09-09 |
DE19809785C2 DE19809785C2 (de) | 2000-02-10 |
Family
ID=7860044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE1998109785 Expired - Fee Related DE19809785C2 (de) | 1998-03-08 | 1998-03-08 | Radioimmunpharmakon zur Behandlung der HIV-1-Infektion |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1061959A2 (de) |
JP (1) | JP2002506051A (de) |
AU (1) | AU3698199A (de) |
DE (1) | DE19809785C2 (de) |
WO (1) | WO1999045969A2 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4497199A (en) * | 1998-04-15 | 1999-11-08 | Ingrid-Corina Bergter | Cd4 radio-immunological pharmaceuticals for the treatment of hiv infections |
AU5503899A (en) * | 1998-06-29 | 2000-01-17 | Wolfgang Bergter | Antiviral and antiretroviral radioimmunomedicaments based on alpha-emitters and beta-emitters |
CN1238499C (zh) * | 2002-07-29 | 2006-01-25 | 清华大学 | 艾滋病病毒0型株的一种抗体及其生产细胞系与应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0251612A2 (de) * | 1986-06-23 | 1988-01-07 | Bristol-Myers Squibb Company | Menschlicher monoklonaler Antikörper gegen Lymphadenopathie assozierten Virus |
WO1988009181A2 (en) * | 1987-05-29 | 1988-12-01 | Tanox Biosystems, Inc. | Monoclonal antibodies neutralizing hiv-1 |
WO1990009805A1 (en) * | 1989-02-28 | 1990-09-07 | New York University | Human monoclonal antibodies to human immunodeficiency virus |
WO1991010742A1 (en) * | 1990-01-16 | 1991-07-25 | Replgien Corporation | Monoclonal antibody specific for non-immunodominant epitope of hiv proteins |
WO1994004191A1 (en) * | 1992-08-13 | 1994-03-03 | Antisoma Limited | Medical treatment |
WO1995010777A1 (en) * | 1993-10-15 | 1995-04-20 | Rakowicz Szulczynska Ewa M | Detection and treatment of breast and gynecological cancer |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1339415C (en) * | 1989-08-24 | 1997-09-02 | Milton David Goldenberg | Detection and treatment of infections with immunoconjugates |
ATE233814T1 (de) * | 1992-09-30 | 2003-03-15 | Scripps Research Inst | Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus |
-
1998
- 1998-03-08 DE DE1998109785 patent/DE19809785C2/de not_active Expired - Fee Related
-
1999
- 1999-03-05 JP JP2000535382A patent/JP2002506051A/ja active Pending
- 1999-03-05 AU AU36981/99A patent/AU3698199A/en not_active Abandoned
- 1999-03-05 EP EP99919038A patent/EP1061959A2/de not_active Withdrawn
- 1999-03-05 WO PCT/DE1999/000598 patent/WO1999045969A2/de not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0251612A2 (de) * | 1986-06-23 | 1988-01-07 | Bristol-Myers Squibb Company | Menschlicher monoklonaler Antikörper gegen Lymphadenopathie assozierten Virus |
WO1988009181A2 (en) * | 1987-05-29 | 1988-12-01 | Tanox Biosystems, Inc. | Monoclonal antibodies neutralizing hiv-1 |
WO1990009805A1 (en) * | 1989-02-28 | 1990-09-07 | New York University | Human monoclonal antibodies to human immunodeficiency virus |
WO1991010742A1 (en) * | 1990-01-16 | 1991-07-25 | Replgien Corporation | Monoclonal antibody specific for non-immunodominant epitope of hiv proteins |
WO1994004191A1 (en) * | 1992-08-13 | 1994-03-03 | Antisoma Limited | Medical treatment |
WO1995010777A1 (en) * | 1993-10-15 | 1995-04-20 | Rakowicz Szulczynska Ewa M | Detection and treatment of breast and gynecological cancer |
Also Published As
Publication number | Publication date |
---|---|
AU3698199A (en) | 1999-09-27 |
WO1999045969A3 (de) | 2000-02-17 |
JP2002506051A (ja) | 2002-02-26 |
DE19809785C2 (de) | 2000-02-10 |
EP1061959A2 (de) | 2000-12-27 |
WO1999045969A2 (de) | 1999-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60038239T2 (de) | Neue klinische parameter zur bestimmung einer hämatologischen toxizität vor einer strahlenimmuntherapie | |
Press et al. | Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas | |
Ingrand | Characteristics of radio-isotopes for intra-articular therapy. | |
Holman et al. | Biodistribution and dosimetry of N-isopropyl-p-[123I] iodoamphetamine in the primate | |
Jurcic | Targeted alpha-particle therapy for hematologic malignancies | |
EP1387701B1 (de) | Immunkonjugate aus eidotter-antikörpern (igy), deren konfektionierung und anwendung in diagnostik und therapie | |
Elgqvist et al. | Fractionated radioimmunotherapy of intraperitoneally growing ovarian cancer in nude mice with 211At-MX35 F (ab′) 2: therapeutic efficacy and myelotoxicity | |
DE19809785C2 (de) | Radioimmunpharmakon zur Behandlung der HIV-1-Infektion | |
Malviya et al. | Radiolabeled humanized anti-CD3 monoclonal antibody visilizumab for imaging human T-lymphocytes | |
Kuzel et al. | A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1 | |
Fink-Bennett et al. | 90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma | |
Kramer et al. | Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates | |
EP1091763B1 (de) | Antivirale und antiretrovirale radioimmunpharmaka auf der basis von alpha- und beta-strahlern | |
DE3850750T2 (de) | Verfahren zur Verhütung von GVHD. | |
Jurcic | Targeted alpha-particle immunotherapy with bismuth-213 and actinium-225 for acute myeloid leukemia | |
DeNardo et al. | Radiation treatment of B cell malignancies with immunoconjugate | |
Avilés et al. | Novel therapy in multiple myeloma | |
DE19826307A1 (de) | CD4-Radioimmunpharmaka zur Behandlung der HIV-Infektion | |
Ledermann et al. | Biodistribution and tumour localisation of 131I SWA11 recognising the cluster w4 antigen in patients with small cell lung cancer | |
Andretta et al. | 99mTc-sestamibi scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients | |
Elster et al. | Disappearance of hyaluronidase from the blood of albino rats | |
Gottschalk et al. | The use of large amounts of radioactive sulfur in patients with advanced chondrosarcomas. I. Clinical and hematologic observations | |
EP1071475A2 (de) | Cd4-radioimmunpharmaka zur behandlung der hiv-infektion | |
Hosain et al. | Revision of gonadal radiation dose to man from thallium-201 | |
DE19818843A1 (de) | Radioimmunpharmaka zur Therapie der Hepatitis C |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
OP8 | Request for examination as to paragraph 44 patent law | ||
8122 | Nonbinding interest in granting licenses declared | ||
AG | Has addition no. |
Ref country code: DE Ref document number: 19818843 Format of ref document f/p: P |
|
AG | Has addition no. |
Ref country code: DE Ref document number: 19826307 Format of ref document f/p: P |
|
AG | Has addition no. |
Ref country code: DE Ref document number: 19828732 Format of ref document f/p: P |
|
AG | Has addition no. |
Ref country code: DE Ref document number: 19828732 Format of ref document f/p: P Ref country code: DE Ref document number: 19826307 Format of ref document f/p: P Ref country code: DE Ref document number: 19818843 Format of ref document f/p: P |
|
D2 | Grant after examination | ||
8323 | Nonbinding interest in granting licenses withdrawn | ||
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |